Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Market

23.26USD
27 Sep 2016
Change (% chg)

-- (--)
Prev Close
$23.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
307,201
52-wk High
$52.88
52-wk Low
$18.21

PTLA.OQ

Chart for PTLA.OQ

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $1,314.21
Shares Outstanding(Mil.): 56.50
Dividend: --
Yield (%): --

Financials

  PTLA.OQ Industry Sector
P/E (TTM): -- 43.70 36.51
EPS (TTM): -4.45 -- --
ROI: -65.19 -0.32 13.85
ROE: -70.70 -3.00 14.77

BRIEF-Portola Pharmaceuticals announces IndexXa review update

* Portola pharmaceuticals announces validation of marketing authorization application (maa) by European Medicines Agency (ema) for indexxa (andexanet alfa), a factor xa inhibitor antidote

Aug 19 2016

Portola's AndexXa fails to get US FDA approval

Aug 18 Portola Pharmaceuticals said on Wednesday its investigational drug AndexXa did not get approval from the U.S. Food and Drug Administration.

Aug 18 2016

CORRECTED-BRIEF-Portola Pharmaceuticals receives Complete Response Letter from FDA for biologics license application for AndexXa

* Portola pharmaceuticals receives complete response letter from fda for biologics license application for andexxa(tm) (andexanet alfa)

Aug 17 2016

BRIEF-Portola Pharmaceuticals reports Q2 loss per share $1.02

* Portola Pharmaceuticals reports second quarter 2016 financial results and provides corporate update

Aug 09 2016

BRIEF-Portola Pharmaceuticals reports $1.15 net loss per share

* Portola pharmaceuticals inc says for Q1 of 2016, Portola reported a net loss of $65.0 million, or $1.15 net loss per share

May 05 2016

BRIEF-Portola signs agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban

* Portola pharmaceuticals enters into clinical collaboration agreement with daiichi sankyo to develop andexanet alfa with edoxaban in japan

Apr 04 2016

BRIEF-Deerfield Mgmt L.P. reports 5.48 pct passive stake in Portola Pharmaceuticals Inc as of March 24, 2016

* Deerfield Mgmt L.P. reports 5.48 pct passive stake in Portola Pharmaceuticals Inc as of March 24, 2016 - SEC Filing Source text - http://1.usa.gov/231JYW1 Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Mar 30 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.